Loading
ביו ויו is a listed company. Its insiders report their share dealings to TASE (ISA). From 18 October 2025 to 18 October 2026, the disclosure feed for ביו ויו logged 22 filings by 9 insiders.
Not one of the filings records a straightforward purchase or sale on the market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Insider buying of ביו ויו has been absent for the past year.
For context, the typical company on the same exchange (median of 530 companies) published 13 filings over the same period, against 22 filings here.
Source: insider filings from TASE (ISA). Past trades are no guide to future returns.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
· cache
22 of 22 declarations
Biyo Viyo is a company listed on the XTAE, specializing in the biotechnology sector. It focuses on developing innovative solutions to enhance human health.
Insider filings
Over the last 90 days, 11 filings published between 5 October and 6 October 2026: no open-market purchase or sale filed by an insider. 11 other filings (not open-market purchases or sales: grants, options, plans, sale notices, block transfers).
Summary written automatically from public filings, without human review. General information, identical for every reader: it is not investment advice or a recommendation to buy or sell. Investing involves a risk of capital loss. Generated on 13 October 2026 (UTC)